Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review - PubMed
5 hours ago
- #targeted therapy
- #metastatic colorectal cancer
- #HER2-positive
- HER2-targeted therapies are being explored for RAS/BRAF wild-type/HER2+ metastatic colorectal cancer (mCRC).
- No regulatory criteria exist for determining HER2 overexpression in mCRC, unlike in breast and gastric cancers.
- Early HER2 testing at mCRC diagnosis is crucial for broadening treatment options and optimizing outcomes.
- Various methods like immunohistochemistry, in situ hybridization, and next-generation sequencing are used to detect HER2 overexpression/amplification in mCRC.
- Clinical trials like MOUNTAINEER and DESTINY-CRC01 support the use of tucatinib + trastuzumab or trastuzumab deruxtecan in HER2+ mCRC.
- Real-world analyses show that HER2 testing is not routinely performed in HER2+ mCRC patients.
- Increased awareness and earlier adoption of HER2 testing are needed to improve treatment options for HER2+ mCRC patients.